Barbara Seitz-Polski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Barbara Seitz-Polski has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
Vesna Brglez
Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, Centre Hospitier Universitaire de Nice, Nice, France
22 shared publicationsSylvia Benzaken
Laboratoire d'Immunologie, CHU de Nice, Université Côte d'Azur, France
18 shared publicationsMaxime Teisseyre
15 shared publicationsCéline Fernandez
Centre Hospitalier Universitaire de Nice, Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, Nice, France
13 shared publicationsDaisy Graça
Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, CHU de Nice, Université Côte d'Azur, France
11 shared publicationsKévin Zorzi
Centre Hospitalier Universitaire de Nice, Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, Nice, France
11 shared publications
Latest Publications
- Open Access
- 7 July 2026
- Published by Elsevier in SSRN Electronic Journal
Functional Immune Profiling Identifies Time-Dependent Infection-Associated Immune States after Kidney Transplantation
Background: Current monitoring after kidney transplantation does not directly measure functional immune competence. We evaluated whether longitudinal functional immune profiling could capture the net state of immunosuppression and identify patients at risk for infection.Methods: We conducted a prospective single-centre study of 134 kidney transplant recipients followed for 24 months. Whole blood was stimulated with anti-CD3 and TLR7/8 ligand before transplantation and at day (D)7-21, 3, 6 and 12 months. IFN-γ was measured by ELISA, and ten additional cytokines by multiplex electrochemiluminescence. Lymphocyte subsets were quantified by flow cytometry. Functional responses were analysed using supervised models and unsupervised clustering.Findings: Before transplantation, recipients displayed cytokine-specific immune imbalance, with reduced IFN-γ and IL-12p70 but increased IL-6, IL-17A, IL-4, and IL-5 compared with controls. After transplantation, profound lymphopenia and broad cytokine suppression occurred, followed by incomplete pathway-specific recovery. Early infections were associated with lower baseline adaptive/regulatory cytokine responses, particularly IL-10 and IL-17A. A baseline IL-10/IL-17A score improved early infection discrimination (AUC=0.80). Late infections were associated with reduced post-transplant innate cytokine responses, especially IL-8 and IL-1β at 3 and 6 months. Unsupervised clustering identified dynamic low-immune states associated with subsequent infection.Interpretation: Functional immune profiling identified temporally distinct immune vulnerabilities after kidney transplantation, supporting further validation of dynamic immune monitoring strategies.
- 7 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessFunctional Immune Profiling Identifies Time-Dependent Infection-Associated Immune States after Kidney Transplantation
Background: Current monitoring after kidney transplantation does not directly measure functional immune competence. We evaluated whether longitudinal functional immune profiling could capture the net state of immunosuppression and identify patients at risk for infection.Methods: We conducted a prospective single-centre study of 134 kidney transplant recipients followed for 24 months. Whole blood was stimulated with anti-CD3 and TLR7/8 ligand before transplantation and at day (D)7-21, 3, 6 and 12 months. IFN-γ was measured by ELISA, and ten additional cytokines by multiplex electrochemiluminescence. Lymphocyte subsets were quantified by flow cytometry. Functional responses were analysed using supervised models and unsupervised clustering.Findings: Before transplantation, recipients displayed cytokine-specific immune imbalance, with reduced IFN-γ and IL-12p70 but increased IL-6, IL-17A, IL-4, and IL-5 compared with controls. After transplantation, profound lymphopenia and broad cytokine suppression occurred, followed by incomplete pathway-specific recovery. Early infections were associated with lower baseline adaptive/regulatory cytokine responses, particularly IL-10 and IL-17A. A baseline IL-10/IL-17A score improved early infection discrimination (AUC=0.80). Late infections were associated with reduced post-transplant innate cytokine responses, especially IL-8 and IL-1β at 3 and 6 months. Unsupervised clustering identified dynamic low-immune states associated with subsequent infection.Interpretation: Functional immune profiling identified temporally distinct immune vulnerabilities after kidney transplantation, supporting further validation of dynamic immune monitoring strategies.
- Open Access
- 28 April 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (8) , e214806
Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS
The differential diagnosis between aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), and multiple sclerosis (MS) can be complex. Kappa free light chain index (KFLC-Index) emerged as an effective biomarker for distinguishing patients with MS from patients with other conditions. The main aim of this study was to assess the diagnostic performance of KFLC-Index in differentiating MOGAD, AQP4-NMOSD, and MS and to compare it with CSF-restricted oligoclonal bands (OCB) performance. We conducted a retrospective case-control study involving 18 French centers through our national NOMADMUS database. Patients were eligible if they received MOGAD or AQP4-NMOSD diagnosis and if OCB status and KFLC-Index levels were available or could be measured retrospectively. As a comparator, we included a group of patients with MS from the Lyon center. We included 303 patients with 140 MOGAD, 37 AQP4-NMOSD, and 126 MS. The sex ratio F/M was 1/1 in the MOGAD group, 5/1 in the NMOSD group, and 4/1 in the MS group. The median age was 38 years in the MOGAD group, 52 in the NMOSD group, and 32 in the MS group. The median KFLC-Index (interquartile range) was the lowest in the MOGAD group (0.60 [0.33-2.09]) with 71% of undetectable CSF-KFLC, intermediate in the NMOSD group (8.85 [3.04-16.78]), and the highest in the MS group (49.90 [16.31-113.39]). KFLC-Index had very good diagnostic performance in differentiating MOGAD from MS (area under the curve [AUC] 0.93, 95% CI 0.9-0.96) with an optimal threshold of 5.7 (95% CI 4.74-6.85), a sensitivity of 0.89 (0.83-0.94), and a specificity of 0.89 (0.83-0.94). KFLC-Index had good performance in differentiating NMOSD from MS (AUC 0.82, 95% CI 0.74-0.88) and MOGAD from NMOSD (AUC 0.77, 95% CI 0.69-0.86). KFLC-Index did not significantly outperformed OCB in separating MOGAD from MS and NMOSD from MS; however, the combination of the 2 tests was more performant than used separately. KFLC-Index is a valuable tool in distinguishing MS from AQP4-NMOSD and MOGAD and provides additional information to that given by OCB. We suggest that KFLC-Index as an additional supporting criterion for the differential diagnosis between MOGAD and MS.
- 28 April 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (8) , e214806
Open AccessDiagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS
The differential diagnosis between aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), and multiple sclerosis (MS) can be complex. Kappa free light chain index (KFLC-Index) emerged as an effective biomarker for distinguishing patients with MS from patients with other conditions. The main aim of this study was to assess the diagnostic performance of KFLC-Index in differentiating MOGAD, AQP4-NMOSD, and MS and to compare it with CSF-restricted oligoclonal bands (OCB) performance. We conducted a retrospective case-control study involving 18 French centers through our national NOMADMUS database. Patients were eligible if they received MOGAD or AQP4-NMOSD diagnosis and if OCB status and KFLC-Index levels were available or could be measured retrospectively. As a comparator, we included a group of patients with MS from the Lyon center. We included 303 patients with 140 MOGAD, 37 AQP4-NMOSD, and 126 MS. The sex ratio F/M was 1/1 in the MOGAD group, 5/1 in the NMOSD group, and 4/1 in the MS group. The median age was 38 years in the MOGAD group, 52 in the NMOSD group, and 32 in the MS group. The median KFLC-Index (interquartile range) was the lowest in the MOGAD group (0.60 [0.33-2.09]) with 71% of undetectable CSF-KFLC, intermediate in the NMOSD group (8.85 [3.04-16.78]), and the highest in the MS group (49.90 [16.31-113.39]). KFLC-Index had very good diagnostic performance in differentiating MOGAD from MS (area under the curve [AUC] 0.93, 95% CI 0.9-0.96) with an optimal threshold of 5.7 (95% CI 4.74-6.85), a sensitivity of 0.89 (0.83-0.94), and a specificity of 0.89 (0.83-0.94). KFLC-Index had good performance in differentiating NMOSD from MS (AUC 0.82, 95% CI 0.74-0.88) and MOGAD from NMOSD (AUC 0.77, 95% CI 0.69-0.86). KFLC-Index did not significantly outperformed OCB in separating MOGAD from MS and NMOSD from MS; however, the combination of the 2 tests was more performant than used separately. KFLC-Index is a valuable tool in distinguishing MS from AQP4-NMOSD and MOGAD and provides additional information to that given by OCB. We suggest that KFLC-Index as an additional supporting criterion for the differential diagnosis between MOGAD and MS.
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Nouveaux marqueurs diagnostiques et pronostiques dans la glomérulonéphrite extra-membraneuse : suivi des anticorps anti-PLA2R1 chez le greffé rénal : caractérisation des épitopes reconnus par les anticorps anti-PLA2R1 : identification d’une nouvelle cible antigénique
La Glomérulonéphrite extra-membraneuse est une maladie auto-immune rare mais grave qui conduit dans 30% des cas à une insuffisance rénale chronique terminale nécessitant le recours à la dialyse ou la greffe rénale. Dans les suites d’une greffe, la GEM récidive dans 30 à 40% des cas. En 2009, l’équipe du Pr. Salant en collaboration avec notre équipe a montré que 70% des patients présentant une GEM étaient porteurs d’anticorps (Ac) dirigés contre le récepteur des phospholipases A2 (PLA2R1). Le titre d’anticorps est corrélé à l’activité de la maladie. Il n’existe actuellement aucun biomarqueur permettant de prédire l’évolution de la fonction rénale d’un patient lors de sa prise en charge : dans 30% des cas les patients présentent une rémission spontanée sans traitement immunosuppresseur. Le traitement de la GEM repose sur un traitement symptomatique et une réévaluation après 6 mois. En cas de maladie active persistante, il faut débuter un traitement immunosuppresseur. Dans les formes graves, cette période d’observation de 6 mois peut être à l’origine de lésions irréversibles. Nous avons validé un test ELISA permettant de quantifier les Ac anti-PLA2R1 au cours du suivi de patients porteurs d’une GEM. Ce test nous a permis de montrer sur une cohorte de 15 patients greffés dans les suites d’une GEM qu’un titre d’Ac anti-PLA2R1 persistant après la greffe était associé à un risque de récidive de la maladie sur le greffon. Nous avons ensuite produit dans des cellules HEK les orthologues de PLA2R1 (les récepteurs humain, lapin et murin).
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Nouveaux marqueurs diagnostiques et pronostiques dans la glomérulonéphrite extra-membraneuse : suivi des anticorps anti-PLA2R1 chez le greffé rénal : caractérisation des épitopes reconnus par les anticorps anti-PLA2R1 : identification d’une nouvelle cible antigénique
La Glomérulonéphrite extra-membraneuse est une maladie auto-immune rare mais grave qui conduit dans 30% des cas à une insuffisance rénale chronique terminale nécessitant le recours à la dialyse ou la greffe rénale. Dans les suites d’une greffe, la GEM récidive dans 30 à 40% des cas. En 2009, l’équipe du Pr. Salant en collaboration avec notre équipe a montré que 70% des patients présentant une GEM étaient porteurs d’anticorps (Ac) dirigés contre le récepteur des phospholipases A2 (PLA2R1). Le titre d’anticorps est corrélé à l’activité de la maladie. Il n’existe actuellement aucun biomarqueur permettant de prédire l’évolution de la fonction rénale d’un patient lors de sa prise en charge : dans 30% des cas les patients présentent une rémission spontanée sans traitement immunosuppresseur. Le traitement de la GEM repose sur un traitement symptomatique et une réévaluation après 6 mois. En cas de maladie active persistante, il faut débuter un traitement immunosuppresseur. Dans les formes graves, cette période d’observation de 6 mois peut être à l’origine de lésions irréversibles. Nous avons validé un test ELISA permettant de quantifier les Ac anti-PLA2R1 au cours du suivi de patients porteurs d’une GEM. Ce test nous a permis de montrer sur une cohorte de 15 patients greffés dans les suites d’une GEM qu’un titre d’Ac anti-PLA2R1 persistant après la greffe était associé à un risque de récidive de la maladie sur le greffon. Nous avons ensuite produit dans des cellules HEK les orthologues de PLA2R1 (les récepteurs humain, lapin et murin).
- Open Access
- 19 November 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 90, 103648
The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial
- 19 November 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 90, 103648
Open AccessThe personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial
- Open Access
Rituximab counteracts loss of tolerance in membranous nephropathy patients through NK-mediated Treg induction
Background: Membranous nephropathy (MN) is a chronic, autoimmune kidney disease characterized by an autoimmune response against podocyte-specific antigens, compromising renal functions. Few studies attempted to mechanistically describe how rituximab influences Th cells and whether this impacts on clinical outcome. Methods: Th cell profile of MN patients was characterized using peripheral blood mononuclear cell samples from a multi-centre, prospective clinical trial. Th cell subsets (Treg, Th17 and Th1) were measured by flow cytometry at baseline and after rituximab treatment during a two years follow-up. In vitro studies on fresh peripheral blood samples and isolated cell populations were performed to investigate the mechanisms through which rituximab induces Treg cells. Findings: Before rituximab treatment, MN patients had a Th17/Treg imbalance when compared to age-matched healthy donors (p=0.004). Responders had significantly higher proportions of Treg cells post-rituximab than non-responders (p=0.037). In vitro , rituximab treatment induced Treg cells when using peripheral blood samples from MN patients, however the induction was lost when isolated T cells were used instead of whole blood (p=0.02). Rituximab did not directly induce Treg cells but required a specific cellular environment composed by at least B and Natural Killer (NK) cells as observed by treating pooled T, B and NK cells. Finally, using complementation assays, we demonstrated that rituximab-mediated Treg induction relied on cytokines, mainly Transforming growth factor β (TGFβ), secreted by activated NK cells. Interpretation: Rituximab induces Treg through cytokines produced by NK cells probably during the mechanism of B cell depletion by antibody-dependent cell-mediated cytotoxicity. This mechanism could potentiate the likelihood of remission in MN patients by counteracting loss of immune tolerance.
Open AccessRituximab counteracts loss of tolerance in membranous nephropathy patients through NK-mediated Treg induction
Background: Membranous nephropathy (MN) is a chronic, autoimmune kidney disease characterized by an autoimmune response against podocyte-specific antigens, compromising renal functions. Few studies attempted to mechanistically describe how rituximab influences Th cells and whether this impacts on clinical outcome. Methods: Th cell profile of MN patients was characterized using peripheral blood mononuclear cell samples from a multi-centre, prospective clinical trial. Th cell subsets (Treg, Th17 and Th1) were measured by flow cytometry at baseline and after rituximab treatment during a two years follow-up. In vitro studies on fresh peripheral blood samples and isolated cell populations were performed to investigate the mechanisms through which rituximab induces Treg cells. Findings: Before rituximab treatment, MN patients had a Th17/Treg imbalance when compared to age-matched healthy donors (p=0.004). Responders had significantly higher proportions of Treg cells post-rituximab than non-responders (p=0.037). In vitro , rituximab treatment induced Treg cells when using peripheral blood samples from MN patients, however the induction was lost when isolated T cells were used instead of whole blood (p=0.02). Rituximab did not directly induce Treg cells but required a specific cellular environment composed by at least B and Natural Killer (NK) cells as observed by treating pooled T, B and NK cells. Finally, using complementation assays, we demonstrated that rituximab-mediated Treg induction relied on cytokines, mainly Transforming growth factor β (TGFβ), secreted by activated NK cells. Interpretation: Rituximab induces Treg through cytokines produced by NK cells probably during the mechanism of B cell depletion by antibody-dependent cell-mediated cytotoxicity. This mechanism could potentiate the likelihood of remission in MN patients by counteracting loss of immune tolerance.
- Open Access
- 23 September 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (12) , 3427-3438
Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation
- 23 September 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (12) , 3427-3438
Open AccessAnti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation
- Open Access
- 3 November 2023
- Published by Elsevier in Kidney International Reports
- Vol. 9 (1) , 134-144
Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence
- 3 November 2023
- Published by Elsevier in Kidney International Reports
- Vol. 9 (1) , 134-144
Open AccessOptimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence
- Open Access
- 22 August 2023
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 43 (8) , 1724-1739
Both Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France
COVID-19 vaccines have significantly decreased the number of severe cases of the disease, but the virus circulation remains important, and questions about the need of new vaccination campaigns remain unanswered. The individual’s protection against SARS-CoV-2 infection is most commonly measured by the level and the neutralizing capacity of antibodies produced against SARS-CoV-2. T cell response is a major contributor in viral infection, and several studies have shown that cellular T cell response is crucial in fighting off SARS-CoV-2 infection. Actually, no threshold of protective immune response against SARS-CoV2 infection has been identified. To better understand SARS-CoV-2-mediated immunity, we assessed both B cell (measuring anti-Spike IgG titer and neutralization capacity) and T cell (measuring IFNγ release assay after specific SARS-CoV2 stimulation) responses to SARS-CoV-2 vaccination with or without virus encounter in a cohort of 367 working volunteers. Vaccinated individuals who had previously been infected had a stronger and more lasting immunity in comparison to vaccinated individuals naive to infection whose immunity started to decline 3 months after vaccination. IFNγ release ≥ 0.285 IU/mL and anti-Spike IgG antibodies ≥ 244 BAU/mL were associated with a sufficient immune response following vaccination preventing future infections. Individuals with comorbidities had a lower chance of reaching the protective thresholds of T cell and B cell responses as identified in multivariate analysis. A combined B cell and T cell analysis of immune responses to determine protective thresholds after SARS-CoV-2 vaccination will allow us to identify individuals in need of a booster vaccine dose, particularly in comorbid subjects.
- 22 August 2023
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 43 (8) , 1724-1739
Open AccessBoth Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France
COVID-19 vaccines have significantly decreased the number of severe cases of the disease, but the virus circulation remains important, and questions about the need of new vaccination campaigns remain unanswered. The individual’s protection against SARS-CoV-2 infection is most commonly measured by the level and the neutralizing capacity of antibodies produced against SARS-CoV-2. T cell response is a major contributor in viral infection, and several studies have shown that cellular T cell response is crucial in fighting off SARS-CoV-2 infection. Actually, no threshold of protective immune response against SARS-CoV2 infection has been identified. To better understand SARS-CoV-2-mediated immunity, we assessed both B cell (measuring anti-Spike IgG titer and neutralization capacity) and T cell (measuring IFNγ release assay after specific SARS-CoV2 stimulation) responses to SARS-CoV-2 vaccination with or without virus encounter in a cohort of 367 working volunteers. Vaccinated individuals who had previously been infected had a stronger and more lasting immunity in comparison to vaccinated individuals naive to infection whose immunity started to decline 3 months after vaccination. IFNγ release ≥ 0.285 IU/mL and anti-Spike IgG antibodies ≥ 244 BAU/mL were associated with a sufficient immune response following vaccination preventing future infections. Individuals with comorbidities had a lower chance of reaching the protective thresholds of T cell and B cell responses as identified in multivariate analysis. A combined B cell and T cell analysis of immune responses to determine protective thresholds after SARS-CoV-2 vaccination will allow us to identify individuals in need of a booster vaccine dose, particularly in comorbid subjects.
- 17 April 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (6) , 785-787
Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy
An abstract is unavailable. This article is available as a PDF only.
- 17 April 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (6) , 785-787
Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy
An abstract is unavailable. This article is available as a PDF only.